ArticleFrontiers in immunology2020
Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Coverage and appropriateness of influenza vaccination in adults ≥ 60 y: Provider contribution and adherence to Italian national recommendations.Human vaccines & immunotherapeutics · 2026Article
- Influenza Vaccination Appropriateness: Insights from the Local Health Unit of Catania During the 2023/2024 and 2024/2025 Seasons.Vaccines · 2025Article
- Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.Vaccine · 2025Article
- From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.Science advances · 2024Article
- Modeling human immune responses to vaccination in vitro.Trends in immunology · 2024Review
- Circular RNA: A promising new star of vaccine.Journal of translational internal medicine · 2023Article
- Restoring Trust: The Need for Precision Medicine in Infectious Diseases, Public Health and Vaccines.Human vaccines & immunotherapeutics · 2023Review
- Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.NPJ vaccines · 2023Article
- Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.Frontiers in immunology · 2023Review
- Will Omics Biotechnologies Save Us from Future Pandemics? Lessons from COVID-19 for Vaccinomics and Adversomics.Biomedicines · 2022Review
- Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.Scientific reports · 2022Article
- Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Perinatally Human Immunodeficiency Virus-Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Precision Vaccine Adjuvants for Older Adults: A Scoping Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies.Open forum infectious diseases · 2022Article
- Adjuvant Discovery via a High Throughput Screen using Human Primary Mononuclear Cells.bioRxiv : the preprint server for biology · 2022Article
- An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.Science translational medicine · 2022Article
- Editorial: Immunity in Compromised Newborns.Frontiers in immunology · 2021Article
- Precision Vaccine Development: Cues From Natural Immunity.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Other than clean drinking water, vaccines have been the most effective public health intervention in human history, yet their full potential is still untapped. To date, vaccine development has been largely limited to empirical approaches focused on infectious diseases and has targeted entire populations, potentially disregarding distinct immunity in vulnerable populations such as infants, elders, and the immunocompromised. Over the past few decades innovations in genetic engineering, adjuvant discovery, formulation science, and systems biology have fueled rapid advances in vaccine research poised to consider demographic factors (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.